Deliver Your News to the World

NCCN Releases Updated Treatment Guidelines for Non-Small Cell Lung Cancer


Recent updates for leukemia and bone cancer also posted on

JENKINTOWN, Pa., October 27, 2005 — The National Comprehensive Cancer Network (NCCN) announces the release of newly updated NCCN Clinical Practice Guidelines in Oncology™ for non-small cell lung cancer (NSCLC). Notable changes in NCCN’s updated NSCLC guidelines are the inclusion of bevacizumab (Genentech’s Avastin) plus chemotherapy as first-line treatment for advanced NSCLC, as well as newly defined principles of pathologic review and information outlining established principles of adjuvant therapy.

“A major advance has been the addition of bevacizumab in combination with chemotherapy as first-line therapy for advanced NSCLC, which is based on results of the Phase II/III trial , ECOG 4599,” said David S. Ettinger, M.D., Associate Director for Clinical Research and Alex Grass Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and NCCN Non-Small Cell Lung Cancer Guidelines Panel Chair.

In ECOG 4599, more than 800 patients with previously untreated advanced non-small cell lung cancer were randomized to receive paclitaxel and carboplatin either with (PCB) or without bevacizumab (PC). The PCB arm vs. the PC arm demonstrated significant improvements in response rates, median progression-free survival, and one- and two-year survival (51.9% vs. 43.7%, and 22.1% vs. 16.9%, respectively). Due to risk of bleeding, bevacizumab with chemotherapy is recommended only for patients with nonsquamous histology, those without known brain metastases, and with any combination chemotherapy effective in treatment of NSCLC that doesn’t cause greater than 10% grade 4 thrombocytopenia.

“NCCN Guidelines Panel members continually update the NCCN Clinical Practice Guidelines in Oncology™ and make recommendations based on explicit review of the evidence in a consensus-driven process,” said William T. McGivney, Ph.D., CEO of NCCN. “As a result, the NCCN guidelines are the most comprehensive and most frequently updated guidelines available.”

Other recently updated NCCN guidelines include those for Acute Myeloid Leukemia (AML), Bone Cancer and Chronic Myelogenous Leukemia (CML). For ease of reference, updated guidelines now contain summary pages identifying changes from previous versions. Developed by NCCN Guidelines Panels comprising respected oncology experts from leading cancer centers across the United States, the NCCN guidelines cover 95 percent of all cancers, and span the continuum of cancer care from early stage to advanced stage disease, and from supportive to palliative care. The updated guidelines are available at

For more information about the NCCN Clinical Practice Guidelines in Oncology™ and other NCCN programs, please contact NCCN at 215-690-0254 or visit

For questions about NCCN or for interview information, please contact Susan Sommerville at 215-690-0254.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 19 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders throughout the health care delivery system. As the arbiter of high-quality cancer care, NCCN emphasizes the importance of and promotes continuous quality improvement, creating and publishing clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. NCCN programs include: Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, Treatment Guidelines for Patients, the Journal of the National Comprehensive Cancer Network (JNCCN), Cancer Resource Lines for Leukemia and Multiple Myeloma, educational conferences and symposia for clinicians, the Oncology Outcomes Database Project, the NCCN Oncology Research Program, NCCN Cancer Case Manager™, and collaborations with managed care organizations.

The NCCN member institutions are:
• City of Hope Cancer Center
• Dana-Farber/Partners CancerCare
• Duke Comprehensive Cancer Center
• Fox Chase Cancer Center
• Huntsman Cancer Institute at the University of Utah
• Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
• Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University
• Memorial Sloan-Kettering Cancer Center
• H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida
• Roswell Park Cancer Institute
• St. Jude Children’s Research Hospital / University of Tennessee Cancer Institute
• Stanford Hospital & Clinics
• University of Alabama at Birmingham Comprehensive Cancer Center
• UCSF Comprehensive Cancer Center
• University of Michigan Comprehensive Cancer Center
• UNMC Eppley Cancer Center at The Nebraska Medical Center
• The University of Texas M. D. Anderson Cancer Center


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.